Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Eigentler

Showing results (91-100 of 127) with videos related to

Pageof 13
Sort By:
Pigment Cell & Melanoma Research|April 8, 2014
In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survivalMoritz Menzel, Diana Meckbach, Benjamin Weide, et al.
Theranostics|May 22, 2023
<i>In vivo</i> imaging of CD8<sup>+</sup> T cells in metastatic cancer patients: first clinical experience with simultaneous [<sup>89</sup>Zr]Zr-Df-IAB22M2C PET/MRIJohannes Schwenck, Dominik Sonanini, Dominik Seyfried, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 17, 2023
S2k Guideline - Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - Update 2022Jürgen C Becker, Ambros J Beer, Viola K DeTemple, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|September 6, 2019
[Dermatoscopy-30 years after the First Consensus Conference]Andreas Blum, Friedrich A Bahmer, Jürgen Bauer, et al.
Ebiomedicine|June 9, 2023
Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastasesEftychia Chatziioannou, Jana Roßner, Thazin New Aung, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 17, 2023
S2k-Leitlinie - Merkelzellkarzinom - Update 2022Jürgen C Becker, Ambros J Beer, Viola K DeTemple, et al.
Cancer Medicine|October 18, 2013
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastasesHeike Niessner, Andrea Forschner, Bernhard Klumpp, et al.
Lancet (London, England)|May 18, 2020
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialLisa Zimmer, Elisabeth Livingstone, Jessica C Hassel, et al.
Journal for Immunotherapy of Cancer|January 25, 2022
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinomaIvelina Spassova, Selma Ugurel, Linda Kubat, et al.
Cancers|April 12, 2022
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in GermanyPeter Mohr, Emilie Scherrer, Chalid Assaf, et al.
Pageof 13

Showing results (91-100 of 127) with videos related to

Sort By:
Pageof 13
Pigment Cell & Melanoma Research|April 8, 2014
In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survivalMoritz Menzel, Diana Meckbach, Benjamin Weide, et al.
Theranostics|May 22, 2023
<i>In vivo</i> imaging of CD8<sup>+</sup> T cells in metastatic cancer patients: first clinical experience with simultaneous [<sup>89</sup>Zr]Zr-Df-IAB22M2C PET/MRIJohannes Schwenck, Dominik Sonanini, Dominik Seyfried, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 17, 2023
S2k Guideline - Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - Update 2022Jürgen C Becker, Ambros J Beer, Viola K DeTemple, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|September 6, 2019
[Dermatoscopy-30 years after the First Consensus Conference]Andreas Blum, Friedrich A Bahmer, Jürgen Bauer, et al.
Ebiomedicine|June 9, 2023
Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastasesEftychia Chatziioannou, Jana Roßner, Thazin New Aung, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 17, 2023
S2k-Leitlinie - Merkelzellkarzinom - Update 2022Jürgen C Becker, Ambros J Beer, Viola K DeTemple, et al.
Cancer Medicine|October 18, 2013
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastasesHeike Niessner, Andrea Forschner, Bernhard Klumpp, et al.
Lancet (London, England)|May 18, 2020
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialLisa Zimmer, Elisabeth Livingstone, Jessica C Hassel, et al.
Journal for Immunotherapy of Cancer|January 25, 2022
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinomaIvelina Spassova, Selma Ugurel, Linda Kubat, et al.
Cancers|April 12, 2022
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in GermanyPeter Mohr, Emilie Scherrer, Chalid Assaf, et al.
Pageof 13